

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2019/173636 A9

(43) International Publication Date
12 September 2019 (12.09.2019)

WIPO | PCT

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 14/725 (2006.01)
C07K 14/78 (2006.01) A61K 39/00 (2006.01)
C07K 16/30 (2006.01) C12N 15/90 (2006.01)

(21) International Application Number:

PCT/US2019/021224

(22) International Filing Date:

07 March 2019 (07.03.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/639,978 07 March 2018 (07.03.2018) US
62/745,151 12 October 2018 (12.10.2018) US
62/783,140 20 December 2018 (20.12.2018) US

(71) Applicant: POSEIDA THERAPEUTICS, INC.
[US/US]; 4242 Campus Point Court, Suite 700, San Diego,
California 92121 (US).

(72) Inventors: OSTERTAG, Eric; 4242 Campus Point Court,
Suite 700, San Diego, California 92121 (US). SHED-
LOCK, Devon; 4242 Campus Point Court, Suite 700, San
Diego, California 92121 (US).

(74) Agent: ELRIFI, Ivor R. et al.; COOLEY LLP, 1299 Penn-
sylvania Avenue, NW, Suite 700, Washington, District of
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:


05 November 2020 (05.11.2020)

(15) Information about Correction:

see Notice of 05 November 2020 (05.11.2020)

(54) Title: CARTYRIN COMPOSITIONS AND METHODS FOR USE

FIGURE 1



(57) Abstract: Disclosed are Centyrin chimeric antigen receptors (CARTyrins), CARTyrin transposons encoding CARTyrins of the disclosure, cells modified to express CARTyrins of the disclosure, as well as methods of making and methods of using the same for adoptive cell therapy. In preferred embodiments, CARTyrins of the disclosure specifically bind to a sequence of prostate specific membrane antigen (PSMA).